Search Result

Isoforms Recommended:	TLR6

Results for "

TLR6

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Toll-like Receptor (TLR) (10) Apoptosis (2) Bacterial (1) ERK (2) IFNAR (1) Interleukin Related (3) JNK (2) mRNA (1) NF-κB (2) NO Synthase (3) p38 MAPK (2) Small Interfering RNA (siRNA) (3) TNF Receptor (3)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (1)
Oligonucleotides:	CpG ODNs (2) Rat Pre-designed siRNA Sets (1) mRNA (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Oligonucleotides

Targets Recommended: Toll-like Receptor (TLR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146244

Agatolimod 1 Publications Verification ODN 2006; PF-3512676; CpG 7909; ODN 7909	Toll-like Receptor (TLR) Bacterial NO Synthase Apoptosis	Infection Cancer
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a *TLR9* agonist and immunomodulator with an EC₅₀ of 180 nM against human *TLR9. Agatolimod activates and upregulates the expression of both TLR9* and *TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19*, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .

HY-150750A

ODN M362 sodium	Toll-like Receptor (TLR) Apoptosis Interleukin Related TNF Receptor IFNAR	Inflammation/Immunology Cancer
ODN M362 sodium is a *TLR9* agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of *TLR9/TLR6*, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .

HY-RS14591

Tlr6 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Toll-like Receptor (TLR)	Others
Tlr6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tlr6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tlr6 Mouse Pre-designed siRNA Set A Tlr6 Mouse Pre-designed siRNA Set A

HY-174522

*Human TLR6* mRNA**	mRNA	Inflammation/Immunology
Human TLR6 mRNA encodes the human toll like receptor 6 (TLR6) protein, a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLR6 interacts with toll-like receptor 2 to mediate cellular response to bacterial lipoproteins.

HY-P10586A

Macrophage-activating lipopeptide 2 TFA MALP-2 TFA	Toll-like Receptor (TLR) NO Synthase	Cardiovascular Disease Metabolic Disease
Macrophage-activating lipopeptide 2 TFA is an agonist of Toll like receptors *TLR-2/TLR-6. Macrophage-activating lipopeptide-2 enhances endothelial nitric oxide synthase (eNOS*) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 enhances endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL) .

HY-RS14592

Tlr6 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Toll-like Receptor (TLR)	Others
Tlr6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tlr6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tlr6 Rat Pre-designed siRNA Set A Tlr6 Rat Pre-designed siRNA Set A

HY-RS14590

TLR6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Toll-like Receptor (TLR)	Others
TLR6 Human Pre-designed siRNA Set A contains three designed siRNAs for TLR6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TLR6 Human Pre-designed siRNA Set A TLR6 Human Pre-designed siRNA Set A

HY-178166

ETI41	Toll-like Receptor (TLR) p38 MAPK TNF Receptor ERK JNK NF-κB Interleukin Related	Inflammation/Immunology
ETI41 is an orally active, selective *TLR* inhibitor that targets the nucleoside-binding Site I on *TLR7* (IC₅₀ = 0.63 μM) and TLR9 (IC₅₀ = 0.16 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5). ETI41 potently inhibits endosomal TLR-mediated pro-inflammatory signaling with nanomolar activity in cellular, biophysical and in vivo assays. ETI41 suppresses the expression of inflammation-associated genes and effectively ameliorates symptoms in mouse models of psoriasis, and systemic lupus erythematosus (SLE). ETI41 can be used for autoimmune and inflammatory diseases research .

HY-P10586

Macrophage-activating lipopeptide 2 MALP-2	Toll-like Receptor (TLR) NO Synthase	Cardiovascular Disease
Macrophage-activating lipopeptide 2 (MALP-2) is an agonist of Toll like receptors *TLR-2/TLR-6. Macrophage-activating lipopeptide-2 can enhance endothelial nitric oxide synthase (eNOS*) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 can enhance endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL) .

HY-178169

ETI60	Toll-like Receptor (TLR) p38 MAPK TNF Receptor ERK JNK NF-κB Interleukin Related	Inflammation/Immunology
ETI60 is an orally active, selective *TLR* inhibitor that targets the nucleoside-binding Site I on TLR7 (IC₅₀ = 0.68 μM) and TLR9 (IC₅₀ = 0.12 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5). ETI60 potently inhibits endosomal TLR-mediated pro-inflammatory signaling with nanomolar activity in cellular, biophysical and in vivo assays. ETI60 modulates the expression of genes associated with inflammation. ETI60 effectively ameliorates symptoms in mouse models of psoriasis, and systemic lupus erythematosus (SLE). ETI60 can be used for autoimmune and inflammatory diseases research .

HY-180507

TLR2/9 antagonist 1	Toll-like Receptor (TLR)	Neurological Disease Inflammation/Immunology Cancer
TLR2/9 antagonist 1 (Compound 24) is a reversible covalent *TLR2* (IC₅₀ = 0.5 μM (TLR2/TLR6); IC₅₀ = 0.6 μM (TLR2/TLR1)) and *TLR9* (IC₅₀ = 0.32 μM) antagonist. TLR2/9 antagonist 1 has no significant effect on other TLR subtypes. TLR2/9 antagonist 1 can be used for studying central nervous system diseases and malignant tumors caused by inflammation .

Cat. No.	Product Name	Target	Research Area